Brain Imaging of Protein Synthesis: What can it tell us about - - PowerPoint PPT Presentation

brain imaging of protein synthesis what can it tell us
SMART_READER_LITE
LIVE PREVIEW

Brain Imaging of Protein Synthesis: What can it tell us about - - PowerPoint PPT Presentation

Brain Imaging of Protein Synthesis: What can it tell us about Fragile X ? 1 R E S E A R CH S T U D Y A T T H E N A T I O N A L I N S T I T U T E O F H E A L T H , U S A C A R O L Y N S M I T H P H D - P I I N N A L O U T A E V , D N


slide-1
SLIDE 1

R E S E A R CH S T U D Y A T T H E N A T I O N A L I N S T I T U T E O F H E A L T H , U S A

C A R O L Y N S M I T H P H D - P I I N N A L O U T A E V , D N P - C L I N I C I A N

Brain Imaging of Protein Synthesis: What can it tell us about Fragile X ?

1

slide-2
SLIDE 2

What are Proteins?

 Proteins are building blocks of living tissue, e.g., cell

membranes

 Proteins are important for both structure and

function

 Proteins are likely involved in the processes of

learning and memory

2

slide-3
SLIDE 3

What is Protein Synthesis?

 Protein Synthesis is the formation of new proteins

from amino acids (tryptophan, leucine, phenylalanine, etc.)

 Protein Synthesis takes place in cells.  The NIMH is the first center to develop a

m ethod for QUANTITATIVE m easurem ent of this fundam ental life process in HUMAN Brain

3

slide-4
SLIDE 4

Why is Protein Synthesis im portant in Fragile X Syndrom e?

 Impaired protein synthesis is the major problem of

Fragile X syndrome

 In Fragile X the gene FMR1 is silenced and its

protein product FMRP is not m ade

 FMRP m ay suppress protein synthesis in

brain

 Does this occur in brains of human subjects with

fragile X syndrome?

 If so, can we quantify and visualize the effect?

4

slide-5
SLIDE 5

How Will the Measurem ent of Protein Synthesis Help in the Understanding and Treatm ent of Fragile X Syndrom e?

 What parts of the brain are affected  Correlation between brain regions affected and

symptoms

 Clinical tool for evaluating the effectiveness of

treatments

5

slide-6
SLIDE 6

How Do We Measure Protein Synthesis in Hum ans?

 Positron Emission Tomography (PET)  We give the research subject LEUCINE, a dietary

AMINO ACID, already present in our body (it is not a medication!)

 We “TAG” the Leucine with Carbon 11  The Leucine is incorporated into protein.  The PET scanner takes images over time, showing

area of protein synthesis in a brain.

6

slide-7
SLIDE 7

What does PET scan do?

 Camera that can measure Carbon-11  It looks similar to an MRI or CAT scanner:

It resemble very much the CAT scan people get in the hospital if they are ill. (It looks like a donut over head, not a close tube. You can talk to you child, hold his hand. A day before we do the scan we let both mother and the son to lay in the scanner for a few times to habituate the kid to the scanner and reduce anxiety)

7

slide-8
SLIDE 8

PET scan machine

8

slide-9
SLIDE 9

PET scan machine

9

slide-10
SLIDE 10

Rates of Cerebral Protein Synthesis (rCPS) in an Awake Human Subject

10 CM

3.5 2.8 2.1 1.4 0.7

rCPS (nmol/g/min)

10

slide-11
SLIDE 11

How do Fragile X subjects hold still during the scan?

 We are looking for the boys who can stay reasonably

quite for 60 minutes.

 It is not a closed tube, parents can be present all the

time, hold the hand of the son, talk to him. We have an interpreter all the time, if you need it

 To date, many normal volunteers and boys with

Fragile X syndrome have been studied awake and

  • sedated. We have not had any side effects or

problems associated with the awake PET scan.

11

slide-12
SLIDE 12

Who we are looking for?

 Boys 18-24 years old with full mutation of Fragile X;  Not on major medications (some meds, like for

ADHD are OK).

 Answering the question I was asked multiple times:

We do not recommend you taking your child off the medication for a sake of study. You can severely jeopardize his health and well-being doing so without advice of your doctor.

12

slide-13
SLIDE 13

Why we are recruiting people here?

 Majority of our patients are from USA but we

have a few persons who came from Europe (Italy, Netherland, Portugal).

 In USA, contrarily to other parts of the world, people

consume much more medications.

 We can’t take people on medications into our study,

So we are looking everywhere in the world to find the right candidates : males, age 18-24, full mutation, not

  • n meds.

13

slide-14
SLIDE 14

Benefits and perks..

 There are no investigational

drugs/ procedures involved in the study.

 We release all the test results to the patients, which

is potentially beneficial for a future treatment/ follow up: blood work, EEG, MRI, Psychological assessment, and a Sleep study.

 Child and his parents can visit USA capital. We pays

all expenses (flight and accommodation)

14

slide-15
SLIDE 15

Benefits and perks (continued)..

 Child and parents can visit USA capital. We pays all

expenses (flight, transportation, hotel and food)

 We help with VISA  We pay for the participation depending on the

degree of involvement. (In addition to the full paid accommodation.

 You feel good from doing right things: advancing

current state of knowledge for the development of treatment for Fragile X syndrome

 We bring you from to the airport, you stay in hotel

  • n our campus and do not have to travel along. Do

not be scared to get lost: we are closely

15

slide-16
SLIDE 16

Shortcut to CRC.lnk

16

slide-17
SLIDE 17

Inside the Children’s Inn (Hotel on our campus)

17

slide-18
SLIDE 18
  • Dr. Carolyn Sm ith lab: Dr. Sm ith is in the

center, Dr. Inna Loutaev is second from left

18

slide-19
SLIDE 19

A few places to see in Washington, DC

19

slide-20
SLIDE 20

Panda in Washington Zoo

20

slide-21
SLIDE 21

Washington monument

21

slide-22
SLIDE 22

Capitol Building

22

slide-23
SLIDE 23

Air and Space Museum

23

slide-24
SLIDE 24

Museum of Natural History

24

slide-25
SLIDE 25

Questions?

Feel free to call:

 Dr. Inna Loutaev: 1-240-444-3201-cell phone,

  • r email:

 loutaev.inna@ nih.gov

25